Next Article in Journal
Lipidomics Analysis of Multilamellar Bodies Produced by Amoeba Acanthamoeba castellanii in Co-Culture with Klebsiella aerogenes
Next Article in Special Issue
Emergence and Spread of Enterobacterales with Multiple Carbapenemases after COVID-19 Pandemic
Previous Article in Journal
Serotypes, Antibiotic Susceptibility, Genotypic Virulence Profiles and SpaA Variants of Erysipelothrix rhusiopathiae Strains Isolated from Pigs in Poland
Previous Article in Special Issue
Bacterial Co-Infections and Antimicrobial Resistance in Patients Hospitalized with Suspected or Confirmed COVID-19 Pneumonia in Kazakhstan
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Brief Report

Dissemination of Clinical Acinetobacter baumannii Isolate to Hospital Environment during the COVID-19 Pandemic

by
Emina Pustijanac
1,*,†,
Jasna Hrenović
2,†,
Mirna Vranić-Ladavac
3,
Martina Močenić
4,
Natalie Karčić
3,
Lorena Lazarić Stefanović
4,
Irena Hrstić
4,
Jasenka Lončarić
4,
Martina Šeruga Musić
2,
Marina Drčelić
2,
Dijana Majstorović
5 and
Ines Kovačić
6
1
Faculty of Natural Sciences, Juraj Dobrila University of Pula, 52100 Pula, Croatia
2
Department of Biology, Faculty of Science, University of Zagreb, 10000 Zagreb, Croatia
3
Public Health Institute of Istria County, 52100 Pula, Croatia
4
General Hospital Pula, 52100 Pula, Croatia
5
Faculty of Medicine, Juraj Dobrila University of Pula, 52100 Pula, Croatia
6
Faculty of Educational Sciences, Juraj Dobrila University of Pula, 52100 Pula, Croatia
*
Author to whom correspondence should be addressed.
These authors contributed equally to this work.
Pathogens 2023, 12(3), 410; https://doi.org/10.3390/pathogens12030410
Submission received: 25 January 2023 / Revised: 24 February 2023 / Accepted: 1 March 2023 / Published: 3 March 2023
(This article belongs to the Special Issue Antimicrobial Resistance Trends in the COVID-19 Pandemic)

Abstract

:
The aim of this study was to find the source of Acinetobacter baumannii in the intensive care unit (ICU) after an outbreak during the coronavirus disease 2019 (COVID-19) pandemic, as there was no A. baumannii detected on usually screened susceptible surfaces. The screening of the ICU environment was done in April 2021 when eleven different samples were taken. One A. baumannii isolate was recovered from the air conditioner and was compared with four clinical A. baumannii isolates obtained from patients hospitalized in January 2021. Isolates were confirmed by matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS), minimum inhibitory concentrations (MICs) were determined, and the multilocus sequence typing (MLST) was performed. The molecular identification of A. baumannii isolates as ST208, the presence of the same blaOXA-23 carbapenemase gene, and the same antibiotic susceptibility profile suggest that the isolate recovered from the air conditioner is the same as the isolates recovered from hospitalized patients. The environmental isolate was recovered three months later than the clinical isolates, emphasizing the ability of A. baumannii to survive on dry abiotic surfaces. The air conditioner in the clinical environment is an important but undoubtedly neglected source of A. baumannii outbreaks, hence, frequent disinfection of hospital air conditioners with appropriate disinfectants is mandatory to mitigate the circulation of A. baumannii between patients and the hospital environment.

1. Introduction

Acinetobacter baumannii is a Gram-negative aerobic coccobacillus perceived as an emerging opportunistic pathogen often associated with multidrug-resistant infections, especially ventilator-associated pneumonia, in vulnerable patients in intensive care units (ICUs) [1,2]. They present the ability to form biofilms and to rapidly acquire resistance determinants to a wide range of antibacterial agents that enable and improve survival and spread in the hospital environment [1,3].
The greatest risk for pathogen transmission within the hospital environment is the activities of healthcare workers, such as hand and glove contamination after contact with the patient, even though the hospital environment itself is an increasingly important reservoir of A. baumannii [4,5,6,7].
Multidrug-resistant A. baumannii has been found on bed curtains, laryngoscopes, patient lifting equipment, anti-decubitus mattresses, pillows, medical charts, bedside cabinets, door handles, mops, sinks, floors, keyboards, telephones, ventilation grates, and equipment for mechanical ventilation and aspiration [4,5,6].
A. baumannii isolates have been seen to survive up to 60 days on different dry inanimate materials such as filter paper, Formica, glass, cotton, and metal [7,8,9,10,11,12]. Moreover, one multidrug-resistant isolate survived on a dry laboratory coat for more than 90 days [13]. The long-term persistence on dry surfaces of the hospital environment confirms the source of the spread of hospital outbreaks. In vitro studies have shown that A. baumannii can endure a wide range of pH values and temperatures in different water media, regardless of the availability of dissolved oxygen [14,15]. The aforementioned certainly raises a serious public health concern, and given that A. baumannii biofilms on glass and ceramic have reduced susceptibility to disinfectants, the disquietude becomes even greater [16].
During the coronavirus disease 2019 (COVID-19) pandemic, A. baumannii was recognized as a frequently implicated pathogen that contributed to outbreaks of multidrug-resistant organisms in both ICU and non-ICU units [17,18]. Numerous factors, such as the appropriate use of personal protective equipment, adherence to hand hygiene protocols, appropriate storage of personal protective equipment, and responsible antibiotic use, may all contribute to outbreaks of multi-drug-resistant organisms in hospital settings. However, these factors can potentially be modified to prevent the transmission of these organisms in healthcare facilities [17]. Throughout the COVID-19 pandemic, healthcare workers faced challenges in implementing standard precautions because they had to wear the same equipment for extended periods, prioritize the continuity of patient care, and concentrate on safeguarding themselves rather than preventing the spread of bacteria in the wards. The combination of overcrowded wards, understaffing, and a shortage of properly trained infection control professionals, along with all the aforementioned factors, resulted in the identification of a significant amount of confirmed and potentially more unidentified outbreaks of A. baumannii during the COVID-19 pandemic [17,19,20,21].
The aim of this study was to find the source of A. baumannii in the ICU after the outbreak, as no A. baumannii was detected on the usually screened susceptible surfaces. In this study, we report the first evidence of clinically relevant A. baumannii disseminated from patient to air conditioner in the ICU environment during the COVID-19 outbreak.

2. Materials and Methods

2.1. Isolation of A. baumannii

The study was performed at General Hospital Pula, a 427-bed hospital in the city of Pula, Croatia. From 1 December 2020, until 6 June 2021, an eight-bed intensive care unit (ICU) for COVID-19 patients was established at the former location of this hospital. During this period, 67 patients with severe COVID-19 symptoms were hospitalized in the ICU, and 29 of them acquired a co-infection with A. baumannii. As a critical aspect of the infection control policy, surveillance cultures were obtained from all 67 patients before their admission to the ICU and then on a weekly basis following their admission, in accordance with hospital protocol. In January 2021, six patients acquired A. baumannii infection. In February and March, the number of patients decreased, and there were no A. baumannii isolated from ICU patients. In spring 2021 the number of severe COVID-19 patients increased again. Co-infection with A. baumannii was detected during April and May in 15 and 8 patients, respectively.
The screening of the ICU environment for A. baumannii was done in April 2021. Eleven samples were collected from the ICU environment. The type and origin of the samples were different and consisted of nine swabs and two material samples (Table 1). Additionally, the hospital conducted an annual environmental screening from 2015 to 2020, which covered the area where a COVID-19 ICU was established in 2020. This resulted in the availability of 110 additional environmental samples with varying origins and sampling outcomes, but A. baumannii was not detected in any of them.
One A. baumannii isolate was recovered from the air conditioner. The sample was a swab from the plastic exhaust fan of the indoor unit. The air conditioner was located at a height of 2.5 m in the ICU room with a total 3.5 m height and a surface area of 40 m2.
Four clinical A. baumannii isolates obtained from patients hospitalized in January 2021 were selected for comparison with the isolate recovered from the air conditioner (Table 2). The clinical isolates from January were the earliest ones identified in the outbreak and they were chosen because they had the greatest time interval with respect to the isolate retrieved from the air conditioner.

2.2. Identification of A. baumannii

The isolation and identification of isolates as the A. baumannii complex was performed by routine bacteriological techniques. Further confirmation of A. baumannii species was done by matrix-assisted laser desorption ionization-time of flight mass spectrometry MALDI-TOF MS (Bruker MALDI Biotyper, software version 5.0.2., Bremen, Germany) on cell extracts. In order to determine the genetic relatedness of A. baumannii isolates, multilocus sequence typing (MLST) was performed according to the Oxford MLST scheme and encompassing seven housekeeping genes (gltA, gyrB, gdhB, recA, cpn60, gpi, and rpoD). Primers and conditioners, as described at PubMSLT (http://pubmlst.org/abaumannii/; accessed on 6 April 2022) were used. Fragments amplified by polymerase chain reaction (PCR) (ProFlex™ 96-Well PCR System, Applied Biosystems, Foster City, CA, USA) were sequenced (commercial service GENEWIZ, Azenta Life Sciences, Griesheim, Germany) and edited using Geneious Prime software (http://www.geneious.com/; accessed on 6 April 2022). Allele sequences and profiles retrieved from the A. baumannii MLST website (http://pubmlst.org/perl/bigsdb/bigsdb.pl?db=pubmlst_abaumannii_oxford_seqdef; accessed on 7 May 2022) were used to determine the sequence type (ST) and international clonal lineage (IC).

2.3. Antibiotic Susceptibility Testing and Detection of Carbapenemase Genes

The susceptibility to carbapenems (meropenem and imipenem), fluoroquinolones (ciprofloxacin and levofloxacin), aminoglycosides (amikacin, gentamicin, and tobramycin), and trimethoprim/sulfamethoxazole were evaluated by the determination of the minimum inhibitory concentration (MIC) values obtained with the Vitek2 system (BioMérieux, Marcy I′Etoile, France). Colistin resistance was tested by the broth microdilution test (Mikrolatest, Erba Lachema, Brno, Czech Republic). The MICs were interpreted according to the recent European Committee on Antimicrobial Susceptibility Testing (EUCAST) breakpoints (v 12.0) for clinical isolates of Acinetobacter spp. (https://www.eucast.org/clinical_breakpoints/, accessed on 6 June 2022).
The presence of acquired genes of the blaOXA lineage that encode OXA-type carbapenemases were searched to explain the molecular mechanism of carbapenem resistance. The multiplex polymerase chain reaction (PCR) with specific primers for blaOXA-40-like, blaOXA-23-like, and blaOXA-58-like genes was performed according to Woodford et al. [22]. Obtained amplified fragments of blaOXA-23-like genes were sequenced, edited, and analyzed according to the protocol described for MLST determination.

3. Results

Regular surveillance cultures were conducted on 67 patients with severe COVID-19 symptoms. The percentage of patients in the ICU department who were infected with A. baumannii during the study period was 43% (Table 3). It is not surprising that all isolates were resistant to carbapenems, as carbapenem resistance in A. baumannii in Croatia had reached 99.5%, according to the Surveillance Atlas of Infectious Diseases of the European Centre for Disease Prevention and Control (https://atlas.ecdc.europa.eu/public/index.aspx?Dataset=27&HealthTopic=4, accessed on 4 February 2023).
From 2015 to 2020, the hospital environment underwent annual screening, and 110 additional samples were obtained. Nevertheless, A. baumannii was not detected in any of the samples collected.
The isolate recovered from the air conditioner, together with four selected clinical isolates, were accurately identified by MALDI-TOF MS as A. baumannii. The MLST revealed that all isolates had the same allele profile and belonged to the ST208 within IC2 (Table 2). The IC2 clonal lineage of A. baumannii is the most widespread among the eight international lineages and is accountable for most of the outbreaks [23,24].
Each one of the five isolates was highly resistant to carbapenems, fluoroquinolones, and aminoglycosides, but remained sensitive to colistin and trimethoprim-sulfamethoxazole (Table 4).
Therefore, isolates could be classified as multidrug-resistant (MDR) according to Magiorakos et al. [25]. All isolates harbored the identical acquired blaOXA-23 carbapenemase gene spread worldwide, which showed 100% sequence ID with numerous sequences deposited in GenBank (for example AJ132105, CP076802, CP045645).

4. Discussion

The molecular identification of A. baumannii isolates as ST208, the presence of the same acquired blaOXA-23 carbapenemase gene, and the same antibiotic susceptibility profile suggest that the isolate recovered from the air conditioner is the same as the isolates recovered from hospitalized patients. The blaOXA-23 is commonly present in the A. baumannii isolates belonging to the IC2 in Croatia [26]. Since it is an acquired carbapenemase gene, its presence in hospital isolates indicates a risk of dissemination of resistance to this last-resort antibiotic [22]. The isolate obtained from the air conditioner displayed varying MIC SXT values, which may have resulted from adaptation to unfavorable environmental conditions. This may be because it was obtained much later than the clinical isolates from the plastic indoor unit of the air conditioner. Bacteria are capable of retaining infection-promoting factors even under stressful conditions, such as prolonged periods of desiccation [11,16]. As a result, co-infection of COVID-19 patients hospitalized in the ICU with this strain could greatly increase the risk factors and complicate the hospital course of patients. Studies during the pandemic have emphasized that co-infection of COVID-19 patients with A. baumannii heightens the likelihood of developing difficult-to-treat infections [11,21].
The air conditioner in the ICU environment where the patients with severe COVID-19 symptoms were hospitalized worked continuously throughout the day and night. It was merely turned off during February and March due to the decreased number of patients. In April, the number of severe COVID-19 patients increased, hence the air conditioner was turned on again and was neither cleaned nor disinfected. The air conditioners in the hospital were regularly mechanically cleaned, nevertheless, they had never been disinfected until after the detection of the A. baumannii isolates.
In a study conducted at General Hospital Pula from 2012 to 2014, various clones of A. baumannii were identified. These clones were predominantly obtained from the ICUs and other hospital departments such as surgery, internal medicine, neurology, and otorhinolaryngology [26]. However, none of these clones were found to be of the ST208 type, which highlights that the outbreak that recently emerged occurred in a newly established ICU. Most probably, the spread of A. baumannii belonging to ST208 to the air conditioner occurred via aerosols from the respiratory tract of the first co-infected patient in this ICU (isolate no. 113). The isolate from the air conditioner was recovered three months later than the clinical isolate no. 113. This is explained by the ability of A. baumannii to survive on dry abiotic surfaces for several months [11,13,27]. After attachment to the abiotic surface, A. baumannii survives in biofilm as viable or even dormant cells [6,11,15,27]. Certain strains of A. baumannii can maintain or even increase their ability to produce biofilms after rehydration and prolonged starvation [6,11]. In addition, biofilms are capable of forming on both living and non-living surfaces and provide protection to bacteria from environmental damage such as host responses, antibiotics, cleansers, and disinfectants [9]. The production of biofilms and their ability to withstand desiccation can heighten the probability of the establishment and persistence of A. baumannii in hospital environments, as well as increase the risk of acquiring antimicrobial resistance, and causing nosocomial infections and outbreaks [6,9,10]
When A. baumannii colonizes an air conditioner, the cells could spread through the hospital room via airflow. This represents a direct source of further infection for immunocompromised patients and even hospital personnel [28,29,30]. Regular service and frequent disinfection of air conditioners in hospital rooms are some of the ways to mitigate the dissemination of clinical A. baumannii to the hospital environment and vice versa. Here, special attention should be given to the resistance of A. baumannii biofilms to commercial disinfectants [16]. The need for the identification of novel disinfectant compounds to treat resistant pathogens, such as A. baumannii, has been recognized and emphasized [31,32].
It can be concluded that the air conditioner in the clinical environment is an important but undoubtedly neglected source of A. baumannii outbreaks. Frequent disinfection of hospital air conditioners with appropriate disinfectants is mandatory to mitigate the circulation of A. baumannii between patients and the hospital environment.

Author Contributions

Conceptualization, E.P. and J.H.; methodology, E.P., M.V.-L. and J.H; validation, M.M., M.Š.M., M.D., D.M. and I.K.; formal analysis, M.M., L.L.S., J.L., M.D., M.V.-L. and N.K.; investigation, M.M., L.L.S., I.H. and J.L.; resources, M.M., L.L.S. and J.L.; data curation, D.M. and I.K.; writing—original draft preparation, E.P. and J.H.; writing—review and editing, E.P. and J.H.; visualization, M.Š.M., M.D., N.K. and I.H.; supervision, E.P. and J.H.; project administration, E.P and J.H.; funding acquisition, I.H. and M.V.-L. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

The data supporting the conclusions of this article are provided within the article. The original data in the present study are available from the corresponding authors.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Peleg, A.Y.; Seifert, H.; Paterson, D.L. Acinetobacter baumannii: Emergence of a Successful Pathogen. Clin. Microbiol. Rev. 2008, 21, 538–582. [Google Scholar] [CrossRef] [Green Version]
  2. Dexter, C.; Murray, G.L.; Paulsen, I.T.; Peleg, A.Y. Community-acquired Acinetobacter baumannii: Clinical characteristics, epidemiology and pathogenesis. Expert Rev. Anti Infect. Ther. 2015, 13, 567–573. [Google Scholar] [CrossRef]
  3. Longo, F.; Vuotto, C.; Donelli, G. Biofilm formation in Acinetobacter baumannii. New Microbiol. 2014, 37, 119–127. [Google Scholar]
  4. Wilks, M.; Wilson, A.; Warwick, S.; Price, E.; Kennedy, D.; Ely, A.; Millar, M.R. Control of an Outbreak of Multidrug-ResistantAcinetobacter baumannii-calcoaceticus Colonization and Infection in an Intensive Care Unit (ICU) Without Closing the ICU or Placing Patients in Isolation. Infect. Control. Hosp. Epidemiol. 2006, 27, 654–658. [Google Scholar] [CrossRef] [PubMed]
  5. Broek, P.V.D.; Arends, J.; Bernards, A.; De Brauwer, E.; Mascini, E.; van der Reijden, T.; Spanjaard, L.; Thewessen, E.; van der Zee, A.; van Zeijl, J.; et al. Epidemiology of multiple Acinetobacter outbreaks in The Netherlands during the period 1999–2001. Clin. Microbiol. Infect. 2006, 12, 837–843. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  6. Russotto, V.; Cortegiani, A.; Raineri, S.M.; Giarratano, A. Bacterial contamination of inanimate surfaces and equipment in the intensive care unit. J. Intensiv. Care 2015, 3, 1–8. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  7. Boyce, J.M. Environmental contamination makes an important contribution to hospital infection. J. Hosp. Infect. 2007, 65, 50–54. [Google Scholar] [CrossRef]
  8. Catalano, M.; Quelle, L.S.; Jeric, P.E.; Di Martino, A.; Maimone, S.M. Survival of Acinetobacter baumannii on bed rails during an outbreak and during sporadic cases. J. Hosp. Infect. 1999, 42, 27–35. [Google Scholar] [CrossRef]
  9. Ibrahim, S.; Al-Saryi, N.; Al-Kadmy, I.M.S.; Aziz, S.N. Multidrug-resistant Acinetobacter baumannii as an emerging concern in hospitals. Mol. Biol. Rep. 2021, 48, 6987–6998. [Google Scholar] [CrossRef]
  10. Espinal, P.; Martí, S.; Vila, J. Effect of biofilm formation on the survival of Acinetobacter baumannii on dry surfaces. J. Hosp. Infect. 2012, 80, 56–60. [Google Scholar] [CrossRef]
  11. Chapartegui-González, I.; Lázaro-Díez, M.; Bravo, Z.; Navas, J.; Icardo, J.M.; Ramos-Vivas, J. Acinetobacter baumannii maintains its virulence after long-time starvation. PLoS ONE 2018, 13, e0201961. [Google Scholar] [CrossRef]
  12. Bravo, Z.; Orruño, M.; Parada, C.; Kaberdin, V.R.; Barcina, I.; Arana, I. The long-term survival of Acinetobacter baumannii ATCC 19606T under nutrient-deprived conditions does not require the entry into the viable but non-culturable state. Arch. Microbiol. 2016, 198, 399–407. [Google Scholar] [CrossRef]
  13. Jakovac, S.; Goić-Barišić, I.; Pirija, M.; Kovačić, A.; Hrenović, J.; Petrović, T.; Tutiš, B.; Tonkić, M. Molecular Characterization and Survival of Carbapenem-Resistant Acinetobacter baumannii Isolated from Hospitalized Patients in Mostar, Bosnia and Herzegovina. Microb. Drug Resist. 2021, 27, 383–390. [Google Scholar] [CrossRef]
  14. Dekic, S.; Hrenovic, J.; Ivankovic, T.; Van Wilpe, E. Survival of ESKAPE pathogen Acinetobacter baumannii in water of different temperatures and pH. Water Sci. Technol. 2018, 78, 1370–1376. [Google Scholar] [CrossRef]
  15. Dekic, S.; Hrenovic, J.; Van Wilpe, E.; Venter, C.; Goic-Barisic, I. Survival of emerging pathogen Acinetobacter baumannii in water environment exposed to different oxygen conditions. Water Sci. Technol. 2019, 80, 1581–1590. [Google Scholar] [CrossRef]
  16. Ivanković, T.; Goić-Barišić, I.; Hrenović, J. Reduced susceptibility to disinfectants of Acinetobacter baumannii biofilms on glass and ceramic. Arch. Ind. Hyg. Toxicol. 2017, 68, 99–108. [Google Scholar] [CrossRef] [Green Version]
  17. Thoma, R.; Seneghini, M.; Seiffert, S.N.; Gysin, D.V.; Scanferla, G.; Haller, S.; Flury, D.; Boggian, K.; Kleger, G.-R.; Filipovic, M.; et al. The challenge of preventing and containing outbreaks of multidrug-resistant organisms and Candida auris during the coronavirus disease 2019 pandemic: Report of a carbapenem-resistant Acinetobacter baumannii outbreak and a systematic review of the literature. Antimicrob. Resist. Infect. Control. 2022, 11, 12. [Google Scholar] [CrossRef]
  18. Polly, M.; de Almeida, B.L.; Lennon, R.P.; Cortês, M.F.; Costa, S.F.; Guimarães, T. Impact of the COVID-19 pandemic on the incidence of multidrug-resistant bacterial infections in an acute care hospital in Brazil. Am. J. Infect. Control. 2021, 50, 32–38. [Google Scholar] [CrossRef]
  19. Falcone, M.; Tiseo, G.; Giordano, C.; Leonildi, A.; Menichini, M.; Vecchione, A.; Pistello, M.; Guarracino, F.; Ghiadoni, L.; Forfori, F.; et al. Predictors of hospital-acquired bacterial and fungal superinfections in COVID-19: A prospective observational study. J. Antimicrob. Chemother. 2020, 76, 1078–1084. [Google Scholar] [CrossRef]
  20. O’Toole, R.F. The interface between COVID-19 and bacterial healthcare-associated infections. Clin. Microbiol. Infect. 2021, 27, 1772–1776. [Google Scholar] [CrossRef]
  21. Russo, A.; Gavaruzzi, F.; Ceccarelli, G.; Borrazzo, C.; Oliva, A.; Alessandri, F.; Magnanimi, E.; Pugliese, F.; Venditti, M. Multidrug-resistant Acinetobacter baumannii infections in COVID-19 patients hospitalized in intensive care unit. Infection 2021, 50, 83–92. [Google Scholar] [CrossRef] [PubMed]
  22. Woodford, N.; Ellington, M.J.; Coelho, J.M.; Turton, J.F.; Ward, M.E.; Brown, S.; Amyes, S.G.; Livermore, D.M. Multiplex PCR for genes encoding prevalent OXA carbapenemases in Acinetobacter spp. Int. J. Antimicrob. Agents 2006, 27, 351–353. [Google Scholar] [CrossRef] [PubMed]
  23. Higgins, P.G.; Dammhayn, C.; Hackel, M.; Seifert, H. Global spread of carbapenem-resistant Acinetobacter baumannii. J. Antimicrob. Chemother. 2009, 65, 233–238. [Google Scholar] [CrossRef] [Green Version]
  24. Higgins, P.G.; Prior, K.; Harmsen, D.; Seifert, H. Development and evaluation of a core genome multilocus typing scheme for whole-genome sequence-based typing of Acinetobacter baumannii. PLoS ONE 2017, 12, e0179228. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  25. Magiorakos, A.-P.; Srinivasan, A.; Carey, R.B.; Carmeli, Y.; Falagas, M.E.; Giske, C.G.; Harbarth, S.; Hindler, J.F.; Kahlmeter, G.; Olsson-Liljequist, B.; et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: An international expert proposal for interim standard definitions for acquired resistance. Clin. Microbiol. Infect. 2012, 18, 268–281. [Google Scholar] [CrossRef] [Green Version]
  26. Ladavac, R.; Bedenić, B.; Vranić-Ladavac, M.; Barišić, N.; Karčić, N.; Pompe, K.; Ferenčić, A.; Stojanović, A.; Seifert, H.; Katić, S.; et al. Emergence of different Acinetobacter baumannii clones in a Croatian hospital and correlation with antibiotic susceptibility. J. Glob. Antimicrob. Resist. 2017, 10, 213–218. [Google Scholar] [CrossRef] [Green Version]
  27. Dekic, S.; Hrenovic, J.; Durn, G.; Venter, C. Survival of extensively- and pandrug-resistant isolates of Acinetobacter baumannii in soils. Appl. Soil Ecol. 2019, 147, 103396. [Google Scholar] [CrossRef]
  28. Allen, K.D.; Green, H.T. Hospital outbreak of multi-resistant Acinetobacter anitratus: An airborne mode of spread? J. Hosp. Infect. 1987, 9, 110–119. [Google Scholar] [CrossRef]
  29. Landelle, C.; Legrand, P.; Lesprit, P.; Cizeau, F.; Ducellier, D.; Gouot, C.; Bréhaut, P.; Soing-Altrach, S.; Girou, E.; Brun-Buisson, C. Protracted Outbreak of Multidrug-Resistant Acinetobacter baumannii after Intercontinental Transfer of Colonized Patients. Infect. Control. Hosp. Epidemiol. 2013, 34, 119–124. [Google Scholar] [CrossRef]
  30. Bai, H.; He, L.-Y.; Wu, D.-L.; Gao, F.-Z.; Zhang, M.; Zou, H.-Y.; Yao, M.-S.; Ying, G.-G. Spread of airborne antibiotic resistance from animal farms to the environment: Dispersal pattern and exposure risk. Environ. Int. 2021, 158, 106927. [Google Scholar] [CrossRef]
  31. Michaud, M.E.; Allen, R.A.; Morrison-Lewis, K.R.; Sanchez, C.A.; Minbiole, K.P.; Post, S.J.; Wuest, W.M. Quaternary Phosphonium Compound Unveiled as a Potent Disinfectant against Highly Resistant Acinetobacter baumannii Clinical Isolates. ACS Infect. Dis. 2022, 8, 2307–2314. [Google Scholar] [CrossRef]
  32. Gregory, T.V.; Ellis, K.; Valeriani, R.; Khan, F.; Wu, X.; Murin, L.; Alibayov, B.; Vidal, A.G.J.; Zhao, T.; Vidal, J.E. MoWa: A Disinfectant for Hospital Surfaces Contaminated With Methicillin-Resistant Staphylococcus aureus (MRSA) and Other Nosocomial Pathogens. Front. Cell. Infect. Microbiol. 2021, 11, 676638. [Google Scholar] [CrossRef]
Table 1. Type, origin of the sample, and colony forming units (CFU) of detected bacteria during the screening of the ICU environment in General hospital Pula occurring in April 2021.
Table 1. Type, origin of the sample, and colony forming units (CFU) of detected bacteria during the screening of the ICU environment in General hospital Pula occurring in April 2021.
Origin of the SampleCFU/SampleDetected Bacteria
Powder for gloves in a plastic cup50Enterococcus faecalis
Powder for gloves—bulk0sterile
Swab from faucet in front of the ICU105Pseudomonas aeruginosa
Swab from faucet in isolation box105Pseudomonas aeruginosa
Swab from faucet in the middle box50Pseudomonas aeruginosa
Swab from patient monitor 10sterile
Swab from patient monitor 20sterile
Swab from faucet in front of the clinic0sterile
Swab from water jug in isolation box0sterile
Swab from stainless steel table for therapy preparation0sterile
Table 2. Origin, date of isolation, and molecular identification of A. baumannii * isolates from general hospital Pula.
Table 2. Origin, date of isolation, and molecular identification of A. baumannii * isolates from general hospital Pula.
IsolateOriginDate of IsolationSequence Type (ST)
1524air conditioner7 April 2021208
113bronchial aspirate5 January 2021208
737tracheal aspirate18 January 2021208
798bronchoalveolar aspirate19 January 2021208
809tracheal aspirate19 January 2021208
* MALDI-TOF MS provided high-confidence species identification for A. baumannii with score values from 2.10 to 2.36.
Table 3. Percentage of patients infected with A. baumannii in the ICU department during the study period.
Table 3. Percentage of patients infected with A. baumannii in the ICU department during the study period.
The Month and the YearNumber of PatientsNumber of Positive PatientsPercentage
December 20201000%
January 20219667%
February 2021100%
March 2021900%
April 2021221568%
May 202116850%
All together672943%
Table 4. Antibiotic * susceptibility profile of A. baumannii isolates from general hospital Pula.
Table 4. Antibiotic * susceptibility profile of A. baumannii isolates from general hospital Pula.
IsolateMIC Values of Antibiotics (mg/L)
IPMMEMCIPLVXAMKGENTOBCSTSXT
1524≥16 R≥16 R≥4 R>2 R≥64 R≥16 R≥16 R0.501.0
113≥16 R≥16 R≥4 R>2 R≥64 R≥16 R≥16 R0.500.5
737≥16 R≥16 R≥4 R>2 R≥64 R≥16 R≥16 R0.500.5
798≥16 R≥16 R≥4 R>2 R≥64 R≥16 R≥16 R0.500.5
809≥16 R≥16 R≥4 R>2 R≥64 R≥16 R≥16 R0.500.5
* MEM, meropenem; IPM, imipenem; CIP, ciprofloxacin; LVX, levofloxacin; AMK, amikacin; GEN, gentamicin; TOB, tobramycin; CST, colistin; and SXT, trimethoprim-sulfamethoxazole. R resistant according to EUCAST criteria. All isolates harbored the identical acquired blaOXA-23 carbapenemase gene.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Pustijanac, E.; Hrenović, J.; Vranić-Ladavac, M.; Močenić, M.; Karčić, N.; Lazarić Stefanović, L.; Hrstić, I.; Lončarić, J.; Šeruga Musić, M.; Drčelić, M.; et al. Dissemination of Clinical Acinetobacter baumannii Isolate to Hospital Environment during the COVID-19 Pandemic. Pathogens 2023, 12, 410. https://doi.org/10.3390/pathogens12030410

AMA Style

Pustijanac E, Hrenović J, Vranić-Ladavac M, Močenić M, Karčić N, Lazarić Stefanović L, Hrstić I, Lončarić J, Šeruga Musić M, Drčelić M, et al. Dissemination of Clinical Acinetobacter baumannii Isolate to Hospital Environment during the COVID-19 Pandemic. Pathogens. 2023; 12(3):410. https://doi.org/10.3390/pathogens12030410

Chicago/Turabian Style

Pustijanac, Emina, Jasna Hrenović, Mirna Vranić-Ladavac, Martina Močenić, Natalie Karčić, Lorena Lazarić Stefanović, Irena Hrstić, Jasenka Lončarić, Martina Šeruga Musić, Marina Drčelić, and et al. 2023. "Dissemination of Clinical Acinetobacter baumannii Isolate to Hospital Environment during the COVID-19 Pandemic" Pathogens 12, no. 3: 410. https://doi.org/10.3390/pathogens12030410

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop